Twelve of the 15 analysts surveyed by S&P Global (NYSE: SPGI) in April rated the pharmaceutical stock as a "buy" or "strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results